Literature DB >> 7535089

Loss of heterozygosity in sporadic primary cutaneous melanoma.

E Healy1, I Rehman, B Angus, J L Rees.   

Abstract

Difficulties in obtaining clinical samples from primary melanomas have meant that most genetic analyses of melanoma have concentrated on cell lines and metastases. Because the Breslow thickness of the primary tumour is the single best prognostic indicator, it is important to identify genetic abnormalities in primary melanomas and relate these changes to the thickness of the lesion. We have investigated 47 sporadic melanomas, of which 41 were primary lesions, for loss of heterozygosity (LOH) on several chromosomal arms, including areas where genes involved in familial melanoma and other relevant hereditary syndromes map, and where LOH has previously been reported in cell lines, or metastatic lesions. LOH was identified at 66 (18%) of 358 informative loci in primary melanomas, and there was a significant relationship between the overall frequency of LOH and Breslow thickness (P < 0.0005). Loss of chromosome arm 9p was most frequent, occurring in 15 (47%) of 32 informative primary tumours, and was observed in 3 of 11 informative lesions < or = 1.5 mm in depth. LOH on chromosome arms 3p, 6q, 10q, 11q, and 17p was also relatively frequent, with loss of 3p and 10q heterozygosity in lesions < or = 1.5 mm in depth, while LOH on 6q, 11q, and 17p was only detected in more invasive tumours. The results suggest that loss of these chromosome regions are important in sporadic cutaneous melanoma, and are consistent with chromosome arm 9p loss occurring before loss of other chromosome arms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535089     DOI: 10.1002/gcc.2870120211

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  17 in total

Review 1.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  Liquid Biopsies for Assessing Metastatic Melanoma Progression.

Authors:  Kelly Huynh; Dave S B Hoon
Journal:  Crit Rev Oncog       Date:  2016

3.  Molecular clonality of in-transit melanoma metastasis.

Authors:  T Nakayama; B Taback; R Turner; D L Morton; D S Hoon
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 4.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

5.  AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.

Authors:  Qiang Zuo; Jing Liu; Liping Huang; Yifei Qin; Teresa Hawley; Claire Seo; Glenn Merlino; Yanlin Yu
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

6.  Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase.

Authors:  Oddbjørn Straume; Johanna Smeds; Rajiv Kumar; Kari Hemminki; Lars Andreas Akslen
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

7.  Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.

Authors:  Bret Taback; Steven J O'Day; Peter D Boasberg; Sherry Shu; Patricia Fournier; Robert Elashoff; He-Jing Wang; Dave S B Hoon
Journal:  J Natl Cancer Inst       Date:  2004-01-21       Impact factor: 13.506

8.  Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.

Authors:  S Huang; D Jean; M Luca; M A Tainsky; M Bar-Eli
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

9.  p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem.

Authors:  N Murphy; C C B B Heffron; B King; U G Ganuguapati; M Ring; E McGuinness; O Sheils; J J O'Leary
Journal:  Virchows Arch       Date:  2004-09-18       Impact factor: 4.064

10.  [DNA copy number changes in the diagnosis of melanocytic tumors].

Authors:  J Bauer; B C Bastian
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.